

Cover Story
ClinicalReal-world Evidence
By Matthew Bin Han Ong
A novel study led by Friends of Cancer Research is providing evidence that tumor response rates can be assessed across real-world data sets, bringing regulators one step closer to potentially building a framework for pre-market evaluation of cancer drugs and post-market tracking of drug performance based on real-world endpoints.
In Brief


Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for October 2023
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- NIH Director Jay Bhattacharya launches a podcast
- Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- As Trump decimates NIH funding, a daring proposal to issue $750 billion in bonds for medical cures garners attention
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- “Forward funding” NIH budget plan would make competing for grants much harder
- Optimizing dosing of expensive and toxic oncology drugs: Making America healthier